Related papers: A bayesian reanalysis of the phase III aducanumab …
The use of amyloid-beta (A$\beta$) clearance to support regulatory approvals of drugs in Alzheimer's disease (AD) remains controversial. We evaluate A$\beta$ as a potential trial-level surrogate endpoint for clinical function in AD using a…
This study investigates the causal relationships between Clinical Dementia Ratings (CDR) and its six domain scores across two distinct aging datasets: the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Longitudinal Aging Study…
Medium-horizon Alzheimer's disease progression prediction is difficult because future clinical scores can remain tied to baseline severity, while biomarker histories are irregular and incompletely observed. We develop an anchor-based…
In early-phase cancer clinical trials, the limited availability of data presents significant challenges in developing a framework to efficiently quantify treatment effectiveness. To address this, we propose a novel utility-based Bayesian…
Alzheimer's disease (AD) is a prevalent, progressive, and ultimately fatal neurodegenerative disorder that is defined pathologically by the accumulation of amyloid plaques and tau neurofibrillary tangles in the brain. There remains an unmet…
Early detection of dementia is critical for timely medical intervention and improved patient outcomes. Neuropsychological tests are widely used for cognitive assessment but have traditionally relied on manual scoring. Automatic dementia…
The phase III BNT162b2 mRNA COVID-19 vaccine trial is based on a Bayesian design and analysis, and the main evidence of vaccine efficacy is presented in Bayesian statistics. Confusion and mistakes are produced in the presentation of the…
We classify very-mild to moderate dementia in patients (CDR ranging from 0 to 2) using a support vector machine classifier acting on dimensionally reduced feature set derived from MRI brain scans of the 416 subjects available in the…
Agitation is one of the most prevalent symptoms in people with dementia (PwD) that can place themselves and the caregiver's safety at risk. Developing objective agitation detection approaches is important to support health and safety of PwD…
Alzheimer's dementia (AD) is of increasing concern as populations achieve longer lifespans. Many of the recent failed AD clinical trials recruiting cognitively intact individuals had a low number of AD events and were thus underpowered.…
Acute brain dysfunction (ABD) is a common, severe ICU complication, presenting as delirium or coma and leading to prolonged stays, increased mortality, and cognitive decline. Traditional screening tools like the Glasgow Coma Scale (GCS),…
Adverse drug reactions considerably impact patient outcomes and healthcare costs in cancer therapy. Using artificial intelligence to predict adverse drug reactions in real time could revolutionize oncology treatment. This study aims to…
Dementia is a syndrome characterised by the decline of different cognitive abilities. Alzheimer's Disease (AD) is the most common dementia affecting cognitive domains such as memory and learning, perceptual-motion or executive function.…
Phase I clinical trials are designed to test the safety (non-toxicity) of drugs and find the maximum tolerated dose (MTD). This task becomes significantly more challenging when multiple-drug dose-combinations (DC) are involved, due to the…
Bayesian response adaptive clinical trials are currently evaluating experimental therapies for several diseases. Adaptive decisions, such as pre-planned variations of the randomization probabilities, attempt to accelerate the development of…
Background. Alzheimer's disease and related dementia (ADRD) are characterized by multiple and progressive anatomo clinical changes. Yet, modeling changes over disease course from cohort data is challenging as the usual timescales are…
With populations ageing, the number of people with dementia worldwide is expected to triple to 152 million by 2050. Seventy percent of cases are due to Alzheimer's disease (AD) pathology and there is a 10-20 year 'pre-clinical' period…
Alzheimer's disease is one of the most common types of neurodegenerative disease, characterized by the accumulation of amyloid-beta plaque and tau tangles. Recently, deep learning approaches have shown promise in Alzheimer's disease…
We present DementiaBank-Emotion, the first multi-rater emotion annotation corpus for Alzheimer's disease (AD) speech. Annotating 1,492 utterances from 108 speakers for Ekman's six basic emotions and neutral, we find that AD patients express…
A number of life threatening neuro-degenerative disorders had degraded the quality of life for the older generation in particular. Dementia is one such symptom which may lead to a severe condition called Alzheimer's disease if not detected…